NVO-Can we break through?The Price is currently testing the resistance trend-line.
Having strong reversal at $45 with quite bullish previous weekly candle closed.
Praying that we can break out of this channel to confirm uptrend soon.
Key facts today
Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
3.337 EUR
13.50 B EUR
38.82 B EUR
3.16 B
About Novo Nordisk A/S Class B
Sector
Industry
CEO
Maziar Mike Doustdar
Website
Headquarters
Bagsværd
Founded
1923
ISIN
DK0062498333
FIGI
BBG000RYSN40
Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.
Related stocks
Novo Nordisk Setup – Is This the Pharma Sector’s Strongest Play?🚀 NVO "Novo Nordisk" – Wealth Strategy Map (Swing/Day Trade)
📈 Trade Plan (Bullish Setup)
Trend Confirmation: The bullish trend is supported by Dow Theory accumulation phase 📊.
Candle Signal: A Heikin Ashi Doji has formed, adding confluence to the setup.
Indicator Alert: LSMA (Least Squares Moving A
$NVO supertrend 3-5x in next 5 years- Don't trade NYSE:NVO but invest.
- NYSE:NVO is in 28 years of uptrend and the innovation DNA of this company will prove the investors yet again.
- Reasons to be bullish on NYSE:NVO
- NYSE:NVO is making pills for weightloss but that not only helps in weight management but also reduces
Market UpdateExited out GLXY position for 83% gain.
FED cuts rates as expected but market has this already priced in.
The AI basket is looking wobbly with price action i do not like.
Positions:
Long Novo Nordisk call option
Short Micron Technology put
Novo Nordisk trail results have been strong compared to
Novo Nordisk NVO It's the time to BUYNovo Nordisk NYSE:NVO For me it is the time to start buying at the current price zone and even buy more if it went lower than this price zone.
My mid-term target is as shown on the chart at 81$
NVO-Do not be shaken out.The bullish divergent on the weekly timeframe still intact, buying pressure was getting stronger as we dips.
This is like a boiling kettle building up pressure to go upwards!
We are very likely to continue going up from here, spectacularly
Mark my words, keep hodl, ignore small dips
Shorters wi
NOVO is looking at a strong bullish bottoming outNYSE:NVO is looking at a strong bullish reversal and is likely to head higher after stochastic shows overbought AND long term stochastic shows clear confirmation of oversold crossover.
Price action shows a clear break out of the downtrend line and with the rounding bottom, the stock is likely to
NVOTaking profits on NVO call up around 63%
Still holding MU short however getting slightly battered here.
Why Did Novo Stock Fall So Sharply YesterdayNovo Nordisk shares plunged nearly 20–23% on July 29, 2025, marking its worst trading day since Black Monday in 1987.
Significant Downgrade of 2025 Financial Outlook
The company revised its sales growth forecast for 2025 down to 8–14%, from its prior guidance of 13–21%, and reduced expected operati
NVO currently consolidatedNVO is a relatively popular stock that entered into a steep downward channel. It arrived at a key support zone that must be throughly tested in order to break out of said downward channel.
A positive outlook is that it looks to be trading below fair value, but could be trading at $50 for next few m
See all ideas
Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
N
XS300255582
Novo Nordisk Finance (Netherlands) BV 3.625% 27-MAY-2037Yield to maturity
3.59%
Maturity date
May 27, 2037
N
XS282046075
Novo Nordisk Finance (Netherlands) BV 3.375% 21-MAY-2034Yield to maturity
3.31%
Maturity date
May 21, 2034
N
XS300255353
Novo Nordisk Finance (Netherlands) BV 3.125% 27-MAY-2033Yield to maturity
3.12%
Maturity date
May 27, 2033
N
XS282045567
Novo Nordisk Finance (Netherlands) BV 3.25% 21-JAN-2031Yield to maturity
2.92%
Maturity date
Jan 21, 2031
N
XS300255329
Novo Nordisk Finance (Netherlands) BV 2.875% 27-AUG-2030Yield to maturity
2.85%
Maturity date
Aug 27, 2030
XS244124704
Novo Nordisk Finance (Netherlands) BV 1.375% 31-MAR-2030Yield to maturity
2.76%
Maturity date
Mar 31, 2030
N
XS282045460
Novo Nordisk Finance (Netherlands) BV 3.125% 21-JAN-2029Yield to maturity
2.63%
Maturity date
Jan 21, 2029
N
XS300255299
Novo Nordisk Finance (Netherlands) BV 2.375% 27-MAY-2028Yield to maturity
2.59%
Maturity date
May 27, 2028
XS234803042
Novo Nordisk Finance (Netherlands) BV 0.125% 04-JUN-2028Yield to maturity
2.48%
Maturity date
Jun 4, 2028
XS244933017
Novo Nordisk Finance (Netherlands) BV 1.125% 30-SEP-2027Yield to maturity
2.40%
Maturity date
Sep 30, 2027
N
XS282044994
Novo Nordisk Finance (Netherlands) BV 3.375% 21-MAY-2026Yield to maturity
2.40%
Maturity date
May 21, 2026
See all NOV bonds
Curated watchlists where NOV is featured.
Frequently Asked Questions
The current price of NOV is 50.090 EUR — it has decreased by −0.42% in the past 24 hours. Watch Novo Nordisk A/S Class B stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on TRADEGATE exchange Novo Nordisk A/S Class B stocks are traded under the ticker NOV.
NOV stock has risen by 3.19% compared to the previous week, the month change is a 2.39% rise, over the last year Novo Nordisk A/S Class B has showed a −55.28% decrease.
We've gathered analysts' opinions on Novo Nordisk A/S Class B future price: according to them, NOV price has a max estimate of 83.52 EUR and a min estimate of 40.09 EUR. Watch NOV chart and read a more detailed Novo Nordisk A/S Class B stock forecast: see what analysts think of Novo Nordisk A/S Class B and suggest that you do with its stocks.
NOV stock is 2.18% volatile and has beta coefficient of 1.55. Track Novo Nordisk A/S Class B stock price on the chart and check out the list of the most volatile stocks — is Novo Nordisk A/S Class B there?
Today Novo Nordisk A/S Class B has the market capitalization of 222.30 B, it has increased by 6.83% over the last week.
Yes, you can track Novo Nordisk A/S Class B financials in yearly and quarterly reports right on TradingView.
Novo Nordisk A/S Class B is going to release the next earnings report on Nov 5, 2025. Keep track of upcoming events with our Earnings Calendar.
NOV earnings for the last quarter are 0.80 EUR per share, whereas the estimation was 0.79 EUR resulting in a 0.46% surprise. The estimated earnings for the next quarter are 0.74 EUR per share. See more details about Novo Nordisk A/S Class B earnings.
Novo Nordisk A/S Class B revenue for the last quarter amounts to 10.28 B EUR, despite the estimated figure of 10.29 B EUR. In the next quarter, revenue is expected to reach 10.27 B EUR.
NOV net income for the last quarter is 3.54 B EUR, while the quarter before that showed 3.89 B EUR of net income which accounts for −8.86% change. Track more Novo Nordisk A/S Class B financial stats to get the full picture.
Novo Nordisk A/S Class B dividend yield was 1.83% in 2024, and payout ratio reached 50.28%. The year before the numbers were 1.35% and 50.35% correspondingly. See high-dividend stocks and find more opportunities for your portfolio.
As of Sep 24, 2025, the company has 76.3 K employees. See our rating of the largest employees — is Novo Nordisk A/S Class B on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Novo Nordisk A/S Class B EBITDA is 21.50 B EUR, and current EBITDA margin is 50.95%. See more stats in Novo Nordisk A/S Class B financial statements.
Like other stocks, NOV shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Novo Nordisk A/S Class B stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Novo Nordisk A/S Class B technincal analysis shows the buy rating today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Novo Nordisk A/S Class B stock shows the sell signal. See more of Novo Nordisk A/S Class B technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.